Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
ESMO Open|September 24, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter studyP Schöffski, A Gazzah, J Trigo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2008
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancerC-H Gow, Y-L Chang, Y-C Hsu, et al.
The European Respiratory Journal|July 2, 2011
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancerT-H Tsai, K-Y Su, S-G Wu, et al.
Cancer Research|June 30, 2001
Global analysis of gene expression in invasion by a lung cancer modelJ J Chen, K Peck, T M Hong, et al.
Journal of the National Cancer Institute|September 20, 2001
Collapsin response mediator protein-1 and the invasion and metastasis of cancer cellsJ Y Shih, S C Yang, T M Hong, et al.
ESMO Open|December 30, 2025
Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective studyS-C Chang, C-Y Huang, Y-C Lai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.
Pageof 3